Tyler Seibert MD PhD Focal Therapy Society Focal.Therapy.UK FDA has not, to my knowledge, granted a ‘cancer treatment indication’ for any focal modality just a ‘tissue ablation’ indication via 510K It was a route FDA offered to device companies Physicians then choose to use those tools to ablate tissue which has cancer in it

Why is radiation held to a higher standard than drugs??

❗️ SUPREMO abstract now up For pN1 patients: overall survival HR 0.82 (0.63-1.05) in favor of CWI Authors conclusions: “No impact of CWI on survival”. No! Their own estimate is for 18% improvement and can only rule out > 37% improvement in survival

🚨 🚨 RCT of SBRT vs RFA for recurrent small HCC HR for local progression free survival a whopping 0.45 (0.95 CI 0.24-0.87) with SBRT vs RFA More data of the inferiority of IR ablation for HCC ascopubs.org/doi/10.1200/JC…

I don't treat HCC, but RFA is clearly inferior to SBRT in this study. The local control (75%) with RFA is poor in absolute terms, and it is excellent (93%) with SBRT. No difference in toxicity (with more abdominal pain in RFA). SBRT is a dominant therapy by these criteria.

It’s an honor to care for patients with the support of outstanding organizations like Levine Cancer and Carolina Panthers

Our group has an employed opportunity for a Radiation Oncologist available - happy to discuss details with anyone interested! careers.astro.org/c/job.cfm?site…

Hot of the press IJROBP - The Red Journal: Role of SABR in oligometastatic head and neck cancer: a GORTEC randomized trial Full text here: doi.org/10.1016/j.ijro…

No April Fool's joke ... it is #HeadAndNeckCancerAwarenessMonth. This includes cancers in the larynx, throat, lips, mouth, nose, and salivary glands. Learn more about symptoms, prevention, & screening resources on the NCI’s website: ow.ly/IKqs50VrKPv

POTEN-C: Nerve-sparing SAbR (NV-SAbR) in PCa: Neil Desai #ESTRO25 Results at 3mo 🛡️🧠 Less nerve damage ⬇️🧻 Fewer bowel/bladder side effects ⬆️🚀 Better sexual function ➡️ Even at higher radiation doses! Smarter treatment = better quality of life.

🚀 New in Journal of Clinical Oncology - ROBOMET shorturl.at/NawNo! SABR vs standard #radiotherapy for painful bone mets. ✅ Pain relief at 1 month: 🔹 SABR (20 Gy single dose): 37% complete response 🔸 versus (8 Gy): 25% complete response ⚡ at 3-months ⬆️ withSABR: 54% vs 31%, p= .048

💡 Proton therapy remains an effective option for localized prostate cancer, but could some patients benefit more than others? I share how ongoing analyses are investigating which subgroups may have an advantage with one modality over the other. The future of proton therapy is

X-torial: Cleaning up the misinformation about Joe Biden and #ProstateCancer that I am reading everywhere. The purpose of this is to provide education from someone who treats and studies PCa for a living, lead the USA National Comprehensive Cancer Network (NCCN) PCa guidelines, hold leadership in NRG Oncology National Cancer Institute

American Cancer Society Matt Cooperberg Jonathan Evan Shoag 🇮🇱🇺🇸 Andrew Vickers Amer. Urol. Assn. ASCO ASTRO PCF Science Todd 〽️ Morgan, MD Edward Schaeffer, MD, PhD NRG Oncology Veracyte, Inc. Elai Davicioni 10/x Unlike many articles state, metastatic disease at presentation, like what Joe Biden has, is not uncommon. The rates have been increasing since 2012 due to the USPSTF recommendations against PSA screening. From for men >75yo you can see increases in men presenting with either

It was a pleasure working with an all-star team to update the former ACR (now Amer. Radium Society) "Appropriate Use" guideline on sinonasal cancer #radonc #hncsm Glenn J. Hanna, M.D. Dr. Danielle Margalit doi.org/10.1002/hed.28…

Happy that Levine Cancer could contribute to this novel study! Congrats to all and to Richard White for the coauthor. Dr.Hadzikadic Gusic

Rising PGY-5s and anyone interested, we have a 5th HN rad onc position Moffitt Cancer Center. If interested in joining a busy team, including me, Dr. M Echevarria, George Q. Yang, MD, and Niema Razavian, MD, reach out and can chat about the position.

In high-income countries, 90% of cancer patients have access to radiotherapy; in middle-income countries it’s 60%; but in low-income countries only 10% of patients benefit from this essential cancer care. The IAEA's #RaysOfHope is here to change those obscene discrepancies. ⤵️

Let me start by clearly stating: some of my best friends are Urologists. 🙂 But: I worry the response to the SEMS RPLND trial on stage 2a/b seminoma may be over-enthusiastic. If my son gets this dz, I would favor carbo x 1 followed by involved node, low dose proton therapy.🧵

Does the addition of MDT to standard of care continuous ADT improve outcomes for oligomet prostate ca? Happy to share the results of EXTEND evaluating this question alongside PI Chad Tang, MD & many others